A case of refractory chordoma of the clivus with a review of therapeutic targets
Current Problems in Cancer: Case Reports, ISSN: 2666-6219, Vol: 8, Page: 100194
2022
- 3Citations
- 4Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent News
Data on Chordomas Published by Researchers at Thomas Hospital (A case of refractory chordoma of the clivus with a review of therapeutic targets)
2022 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Investigators discuss new findings in chordomas. According to news
Case Description
Chordomas are rare slow-growing tumors of the bone that are locally aggressive and arise from embryonic remnants of the notochord. The clinical presentation of chordomas is dependent on the site of the neoplasm. Brain MRI remains the preferred diagnostic modality imaging modality followed by a tissue biopsy to confirm the underlying pathology and the classical presence of physaliphorous cells. The mainstay of treatment remains surgical resection with adjuvant radiotherapy with a limited role of conventional chemotherapy. For locally advanced tumors, the prognosis remains poor despite multimodality treatment. In this report, we highlight a case of recurrent clival chordomas with disease progression even with several surgical resections and radiotherapy treatment. Our patient presented with intermittent diplopia and further investigation confirmed clival chordoma. The patient was disease-free for 7 years post initial surgical resection and adjuvant radiotherapy but eventually had multiple disease recurrences. We will be discussing ongoing clinical trials in the management of clival chordomas and emerging potential therapies. As with many rare cancers, access to tumor profiling and finding actionable targets through precision medicine, play a crucial role in improving outcomes. It is imperative that further studies and clinical trials are instituted to influence clinical outcomes.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2666621922000588; http://dx.doi.org/10.1016/j.cpccr.2022.100194; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85139841578&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S2666621922000588; https://dx.doi.org/10.1016/j.cpccr.2022.100194
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know